Stroke Clinical Trial
Official title:
Anti-platelet Precision Medicine to Prevent Stroke Early Progression and Recurrence (PRECISE)
NCT number | NCT03701360 |
Other study ID # | PRECISE |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | October 30, 2018 |
Est. completion date | July 14, 2021 |
Verified date | February 2022 |
Source | Asan Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This is a pragmatic, multi-center, non-interventional, non-randomized prospective observational study.
Status | Completed |
Enrollment | 1199 |
Est. completion date | July 14, 2021 |
Est. primary completion date | July 14, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years and older |
Eligibility | Inclusion Criteria: 1. Male and/or female subjects who are aged 19 or over. 2. Patients with acute non-cardiac stroke or transient ischemic attack within 72 hours of the onset (in the case of a transient ischemic attack, presence of ischemic/ischemic lesion on DWI or PWI). 3. Patients whose informed consent document within 72 hours of onset was signed and submitted. 4. Patients who were treated with aspirin alone or aspirin plus clopidogrel resinate following stroke. Exclusion Criteria: 1. Patients who need anticoagulants for cardiac ischemic stroke or other reasons. 2. Patients who suffered severe stroke (National Institutes of Health Stroke Scale> 16). 3. Patients who received emergency remission therapies such as tPA and thrombolysis. 4. Patients with neurological deterioration prior to signing an informed written consent document. 5. Patients who have undergone patency procedures (surgery or stent insertion) in the cerebrovascular or carotid arteries following stroke or are expected to do so. 6. Patients who are scheduled to undergo major surgery. 7. Patients who developed stroke during procedure/surgery. 8. Patients with recent history (in the past three months) of cerebral hemorrhage. 9. Patients with active internal bleeding. 10. Patients with severe anemia (Hb <10 g / dL) or bleeding tendency (platelet <100,000 / uL or PT-INR> 1.7). 11. When a patient's life expectancy is less than 6 months due to other systemic disease. |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Dong-Wha Kang | Seoul |
Lead Sponsor | Collaborator |
---|---|
Asan Medical Center |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of patients with neurological deterioration under hospital treatment. | Rapid worsening of an existing focal neurological deficit or rapid onset of a new focal neurological deficit (= 24 hours) that is clinically judged by the Investigator not to be attributable to non-ischemic etiology. | up to 3 months after stroke onset | |
Primary | Rate of patients with new ischemic stroke under hospital treatment. | Rapid onset of a new focal neurological deficit with clinical or imaging evidence of infarction and not attributable to a non-ischemic etiology (not associated with brain infection, trauma, tumor, seizure, severe metabolic disease, or degenerative neurological disease); or, Rapid worsening of an existing focal neurological deficit that is judged by the Investigator to be attributable to a new infarction. Criteria for symptoms attributable to new infarction may include symptoms that persist and are judged by the investigator to be attributable to new infarction, imaging evidence of infarction, or no evidence of a non-ischemic etiology. |
up to 3 months after stroke onset | |
Primary | Rate of patients with symptomatic hemorrhagic transformation of an ischemic stroke under hospital treatment. | Imaging evidence (by CT or MR) of extravascular blood within the area of infarction, and symptoms judged to be related to the hemorrhagic transformation. Scenarios which may be judged as symptomatic: If blood is already present on imaging at presentation, symptoms are out of proportion to what would be expected for the size and location of the infarct at presentation; Clinical deterioration, defined by an increase of 4 points or more in the score on the NIHSS or leading to death, occurring after the initial ischemic event, and identified as the result of the hemorrhagic transformation; or Mass effect secondary to the hemorrhagic transformation causing symptoms. |
up to 3 months after stroke onset | |
Primary | Rate of patients with symptomatic intracranial hemorrhage under hospital treatment. | Evidence of hemorrhage in the brain parenchyma or extraparenchymal spaces demonstrated by head imaging, surgery, or autopsy, which is not in the same territory of an underlying acute or subacute ischemic stroke, and is judged to be associated with any new neurologic symptoms (including headache) or leading to death. | up to 3 months after stroke onset | |
Primary | Rate of patients with myocardial infarction under hospital treatment. | The diagnosis of MI will be based on an algorithm developed from the Universal Definition of Myocardial Infarction (Circulation 2007 116:2634-2653) that takes into account 5 categories of clinical information from the acute event: rise and/or fall of cardiac biomarkers, ECG abnormalities, clinical setting, imaging evidence, and pathology. | up to 3 months after stroke onset | |
Primary | Rate of patients with coronary revascularization without myocardial infarction under hospital treatment. | Documented coronary angioplasty, stenting, or bypass surgery for demonstrated or presumed coronary artery disease. | up to 3 months after stroke onset | |
Primary | Rate of patients with major hemorrhage other than intracranial hemorrhage under hospital treatment. | A hemorrhagic event, judged to be nontraumatic, that results in intraocular bleeding causing loss of vision, the need for a transfusion of two or more units of red cells or the equivalent amount of whole blood, or the need for hospitalization or prolongation of existing hospitalization. This may include bleeding events related to surgical procedures but not those related to accidental trauma. Life-threatening hemorrhagic events will be defined as those that are fatal or require use of intravenous inotropic medication to maintain blood pressure, interventional treatment (including surgical, endoscopic or endovascular interventions), or transfusion of four or more units of red cells or the equivalent amount of whole blood. Non-life-threatening hemorrhagic events will be defined as those classified as major hemorrhagic events but not as life-threatening. | up to 3 months after stroke onset | |
Primary | Rate of patients with minor hemorrhage other than intracranial hemorrhage under hospital treatment. | All hemorrhagic events leading to interruption of therapy or discontinuation of the study drug but not classifiable as major hemorrhagic events. This may include bleeding events related to surgical procedures but not those related to accidental trauma. | up to 3 months after stroke onset | |
Primary | Rate of patients with ischemic vascular death under hospital treatment. | Death due to ischemic stroke, myocardial infarction, sudden cardiac death, arrhythmia, pulmonary embolism, bowel or limb infarction, or any death not readily attributable to a non-ischemic cause. | up to 3 months after stroke onset | |
Primary | Rate of patients with hemorrhagic vascular death under hospital treatment. | Death due to intracranial or systemic hemorrhage. | up to 3 months after stroke onset | |
Primary | Rate of patients with other serious adverse event under hospital treatment. | Any adverse event, not belonging to the other outcome event categories, that is fatal or life threatening, is permanently or substantially disabling, requires or prolongs hospitalization, results in a congenital anomaly, or requires intervention to prevent permanent impairment or damage. | up to 3 months after stroke onset | |
Secondary | Evaluation by an independent investigator | A direct comparison between the aspirin alone group and the aspirin plus clopidogrel group for the incidence of 11 outcome variables evaluated by an independent investigator at the primary endpoints will be conducted. | up to 3 months after stroke onset |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04043052 -
Mobile Technologies and Post-stroke Depression
|
N/A | |
Completed |
NCT04034069 -
Effects of Priming Intermittent Theta Burst Stimulation on Upper Limb Motor Recovery After Stroke: A Randomized Controlled Trial
|
N/A | |
Completed |
NCT04101695 -
Hemodynamic Response of Anodal Transcranial Direct Current Stimulation Over the Cerebellar Hemisphere in Healthy Subjects
|
N/A | |
Suspended |
NCT03869138 -
Alternative Therapies for Improving Physical Function in Individuals With Stroke
|
N/A | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Completed |
NCT00391378 -
Cerebral Lesions and Outcome After Cardiac Surgery (CLOCS)
|
N/A | |
Recruiting |
NCT06204744 -
Home-based Arm and Hand Exercise Program for Stroke: A Multisite Trial
|
N/A | |
Active, not recruiting |
NCT06043167 -
Clinimetric Application of FOUR Scale as in Treatment and Rehabilitation of Patients With Acute Cerebral Injury
|
||
Enrolling by invitation |
NCT04535479 -
Dry Needling for Spasticity in Stroke
|
N/A | |
Completed |
NCT03985761 -
Utilizing Gaming Mechanics to Optimize Telerehabilitation Adherence in Persons With Stroke
|
N/A | |
Recruiting |
NCT00859885 -
International PFO Consortium
|
N/A | |
Recruiting |
NCT06034119 -
Effects of Voluntary Adjustments During Walking in Participants Post-stroke
|
N/A | |
Completed |
NCT03622411 -
Tablet-based Aphasia Therapy in the Chronic Phase
|
N/A | |
Completed |
NCT01662960 -
Visual Feedback Therapy for Treating Individuals With Hemiparesis Following Stroke
|
N/A | |
Recruiting |
NCT05854485 -
Robot-Aided Assessment and Rehabilitation of Upper Extremity Function After Stroke
|
N/A | |
Active, not recruiting |
NCT05520528 -
Impact of Group Participation on Adults With Aphasia
|
N/A | |
Active, not recruiting |
NCT03366129 -
Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
|
||
Completed |
NCT05805748 -
Serious Game Therapy in Neglect Patients
|
N/A | |
Completed |
NCT03281590 -
Stroke and Cerebrovascular Diseases Registry
|
||
Recruiting |
NCT05993221 -
Deconstructing Post Stroke Hemiparesis
|